UBS has reiterated its Sell rating on PB Fintech, assigning a target price of ₹1,640 per share, citing mixed signals on growth momentum across verticals.
According to the brokerage, while management guidance remains unchanged, the renewal business is expected to drive profitability in the near term. However, growth in the savings segment has been slower than expected, even as health and term insurance continue to show strong traction.
UBS also noted that Paisabazaar, PB Fintech’s lending marketplace, is set to expand its product offerings, while the company’s healthcare arm, PB Healthcare, will function as a separate entity, allowing for more focused operations and possibly unlocking value over time.
Disclaimer: The views expressed are those of the brokerage firm and do not constitute investment advice by Business Upturn.
